Company intelligence / Profile preview
SELLAS Life Sciences Group, Inc.
New York, New York, United Statessellaslifesciences.com ↗
- Ownership
- Public · SLS
- Employees
- ~15
- Development stage
- Other
01
Overview
SELLAS has reported positive outcomes from the interim analysis of its pivotal Phase 3 REGAL trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia, with the final analysis planned upon reaching 80 events, anticipated in 2025. The company has also reported positive Overall Survival and Overall Response Rate data from the ongoing Phase 2 trial of SLS009 (Tambiciclib) in relapsed/refractory AML, with 8.9 months median Overall Survival in patients with AML-Myelodysplasia-Related Changes and 8.8 months in all patients relapsed or refractory to Venetoclax-based regimens, surpassing the historical benchmark of 2.5 months. An Overall Response Rate of 67% was achieved in patients with AML-MRC.[1][9]
- Therapeutic areas
- Oncology
- Modalities
- Cancer immunotherapeutic agent (peptide immunotherapy)Small molecule inhibitor
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Memorial Sloan Kettering Cancer Center (MSKCC)3D Medicines Inc.GenFleet Therapeutics (Shanghai) Inc.Merck & Co., Inc.
04
Financials
- Market cap
- $1.6B
- Total revenue
- $0
- Enterprise value
- $1.5B
Beyond the preview
Go deeper on SELLAS Life Sciences Group, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SELLAS Life Sciences Group, Inc..